|
Volumn 2, Issue 4, 2001, Pages 195-204
|
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease
|
Author keywords
Arterial disease; Bezafibrate; Fibrinogen; Lipid profile
|
Indexed keywords
BEZAFIBRATE;
C REACTIVE PROTEIN;
CHOLESTEROL;
CREATININE;
FIBRINOGEN;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
LIPID;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
TRIACYLGLYCEROL;
ADULT;
AGED;
ARTERY DISEASE;
ARTICLE;
CHOLESTEROL BLOOD LEVEL;
CLINICAL STUDY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CREATININE BLOOD LEVEL;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
FIBRINOGEN BLOOD LEVEL;
GASTROINTESTINAL SYMPTOM;
HUMAN;
INCIDENCE;
INFLAMMATION;
ISCHEMIC HEART DISEASE;
LEG;
MAJOR CLINICAL STUDY;
MALE;
METABOLISM;
MULTICENTER STUDY;
RANDOMIZED CONTROLLED TRIAL;
SCREENING;
SIDE EFFECT;
STROKE;
TRIACYLGLYCEROL BLOOD LEVEL;
|
EID: 0034889909
PISSN: 14686708
EISSN: None
Source Type: Journal
DOI: 10.1186/CVM-2-4-195 Document Type: Article |
Times cited : (31)
|
References (26)
|